[Treatment of female urinary incontinence].
Bauer
R M
RM
Beckenbodenzentrum Klinikum der Universität München-Grosshadern, Ludwig-Maximilians-Universität. Ricarda.Bauer@med.uni-muenchen.de
Gozzi
C
C
Mayer
M
M
Gratzke
C
C
Soljanik
I
I
Bastian
P J
PJ
Stief
C G
CG
Dannecker
C
C
D018759:Adrenergic Uptake Inhibitors / Q000627:therapeutic use; D019274:Botulinum Toxins, Type A / Q000627:therapeutic use; D018680:Cholinergic Antagonists / Q000627:therapeutic use; D003430:Cross-Sectional Studies; D000068736:Duloxetine Hydrochloride; D005260:Female; D006801:Humans; D008019:Life Style; D012307:Risk Factors; D053825:Suburethral Slings; D013876:Thiophenes / Q000627:therapeutic use; D016896:Treatment Outcome; D014549:Urinary Incontinence / Q000145:classification / Q000453:epidemiology / Q000209:etiology / Q000628:therapy*
D018759:Adrenergic Uptake Inhibitors; D018680:Cholinergic Antagonists; D013876:Thiophenes; D000068736:Duloxetine Hydrochloride; D019274:Botulinum Toxins, Type A